- Home
- IMAX vs TARS Comparison
IMAX vs TARS Comparison
Compare IMAX & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IMAX | TARS |
|---|---|---|
| Founded | 1967 | 2016 |
| Country | Canada | United States |
| Employees | 679 | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.7B |
| IPO Year | 1997 | 2020 |
Fundamental Metrics
Financial Performance| Metric | IMAX | TARS |
|---|---|---|
| Price | $41.92 | $61.51 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 6 |
| Target Price | $44.50 | ★ $89.00 |
| AVG Volume (30 Days) | ★ 832.9K | 529.2K |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 31.25 | ★ 48.21 |
| EPS | ★ 0.07 | N/A |
| Revenue | $410,212,000.00 | ★ $451,360,000.00 |
| Revenue This Year | $9.79 | $56.43 |
| Revenue Next Year | $7.51 | $30.19 |
| P/E Ratio | $619.43 | ★ N/A |
| Revenue Growth | 16.47 | ★ 146.71 |
| 52 Week Low | $24.20 | $38.51 |
| 52 Week High | $45.52 | $85.25 |
Technical Indicators
Market Signals| Indicator | IMAX | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 53.15 | 46.90 |
| Support Level | $34.90 | $60.95 |
| Resistance Level | $43.16 | $66.36 |
| Average True Range (ATR) | 1.58 | 2.87 |
| MACD | -0.10 | 0.39 |
| Stochastic Oscillator | 45.03 | 27.43 |
Price Performance
Historical ComparisonAbout IMAX Imax Corporation
Imax Corp is a technology platform for entertainment and events. Through its proprietary software, auditorium architecture, patented intellectual property, and specialized equipment, IMAX offers end-to-end solution to create superior, immersive content experiences for which the IMAX brand is globally renowned. The Company has two reportable segments being Content Solutions and Technology Products and Services. The Company leverages its proprietary technology and engineering in all aspects of its business, which principally consists of the IMAX film remastering and the sale or lease of premium IMAX theater systems.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.